Company profile
UK company 12620906, incorporated on 26 May 2020.
Home page - VaxEquity
VaxEquity is a UK biotechnology company developing next generation self-amplifying RNA and mRNA therapeutics and vaccines.
Company number 12620906
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
Company registered at Companies House
VaxEquity was founded in 2020 by Imperial College and Morningside. VaxEquity develops transformative RNA therapeutics and vaccines using its next generation self-amplifying RNA platform.VaxEquity uses saRNA to provide extended duration of protein expression. This enables lower doses to be used for vaccines and higher protein levels to be achieved for therapeutics. VaxEquity is pioneering a next generation approach by modifying its self-amplifying RNA (saRNA) to modulate the innate immune response and thereby overcoming current limitations. The flexibility of the Company's platform ensures that its broad pipeline of assets can be designed, developed and manufactured rapidly and at scale.
AstraZeneca has provideed VaxEquity with £195 million of R&D funding and has invested in the biotech as part of a long-term effort to optimize and validate the saRNA platform. In return, AstraZeneca will gain a chance to work with VaxEquity on up to 26 drug targets.
1 Jun 2023 to 31 May 2024
The potential of nucleic acids as vaccines and therapeutics is only just being realised and the success of the Covid mRNA vaccines is due in part to the rate at which scale-up and manufacture was possible. VaxEquity is a biotechnology company seeking to develop novel, second-generation RNA based vaccines and therapeutics. Working in collaboration with the...
